SCYNEXIS SCYX 深 滬
等待開盤 07-22 09:30:00 美东时间
0.7115
-0.013
-1.86%
華盛通- 最 高0.742
- 今 開0.73
- 成交量 11.95万股
- 最 低 0.701
- 昨 收 0.725
- 總市值 2776.29万
- 52周最高 2.21
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.66
- 委 比 83.22%
- 總股本 3902.03万
- 歷史最高 150.00
- 量 比 0.35
- 振 幅 5.66%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SCYNEXIS Holds Annual Meeting, Re-elects Directors
SCYNEXIS ( ($SCYX) ) just unveiled an update. On June 25, 2025, SCYNEXIS, Inc. ...
07-02 04:41
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS announced the resumption of patient dosing in its Phase 3 MARIO study for oral ibrexafungerp after the FDA lifted its clinical hold. This restart triggers a $10 million milestone payment from GSK, with an additional $20 million due in six months. Despite the milestone disputes between SCYNEXIS and GSK, patient enrollment has resumed, with nearly 25% of projected patients already enrolled. The study aims to evaluate ibrexafungerp as a ste...
05-28 12:30
SCYNEXIS Faces Challenges Amidst Antifungal Developments
SCYNEXIS Inc ( ($SCYX) ) has released its Q1 earnings. Here is a breakdown of t...
05-20 11:52
SCYNEXIS shares are trading lower following Q1 reported financial results.
SCYNEXIS shares are trading lower following Q1 reported financial results.
05-16 21:13
SCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Estimate, Sales $257.00K Beat $205.50K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 1200 percent decrease over earnings of $0.01 per share from the same
05-16 04:50
FDA计划逐步淘汰动物实验 首个基因替代疗法药物国内上市 映恩生物即将在港股上市 | 医药投向标
① 国家药监局公开征求医疗器械分类规则意见；国家药监局发文支持境外已上市药品尽早用于临床。 ② FDA计划逐步淘汰动物实验。 ③ 锦波生物国内首个中面部重组Ⅲ型“胶原蛋白填充剂”获批；国内首个基因替代疗法药物上市。 ④ 觅投克生物、睿健医药完成融资。
04-14 07:40
阳光德美助力翰森制药抗真菌新药艾瑞芬净国内获批！
2025年4 月 8 日，翰森制药申报的艾瑞芬净（Ibrexafungerp Tablets；研发代号：HS-10366）获批上市，用于成年和初潮后女性外阴阴道...
04-10 14:07
SCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy
04-08 20:57
Ironwood医药盘中异动 大幅下跌5.30%报4.20美元
北京时间2025年01月03日03时36分，Ironwood医药（IRWD.us）股票出现波动，股价急速下跌5.30%。截至发稿，该股报4.20美元/股，成交量...
01-03 03:36
